Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Get news By email or subscribe to our News feeds.
Posted Yesterday in Daily MedNews
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Former Head of Salmonella-Linked Peanut Firm Now a Consultant
Even though he's under investigation for his role in a peanut-related salmonella outbreak that killed nine people and sickened hundreds in the United States, Stewart Parnell is working as a consultant to peanut companies, says the...
Read More... Posted Yesterday in Daily MedNews
-- Here are the latest clinical trials, courtesy of ClinicalConnection.com:
Pediatric GERD
This study is for babies that seem to have a stomach ache, are fussy, or spit up frequently. If your baby has any of these symptoms, it is possible he or she may have gastroesophageal reflux disease (GERD).
The research site is in Houston, Texas.
More information
Please see...
Read More... Posted Yesterday in Daily MedNews.
WEDNESDAY, Sept. 8 -- Mutations in two genes may be associated with one of the most deadly types of ovarian cancer, U.S. researchers have found.
In the study, researchers at the Johns Hopkins Kimmel Cancer Center looked for mutations in 18,000 protein-encoding genes in ovarian clear cell tumors from eight patients. The investigators found 268 mutations in 253 genes, with an average of 20...
Read More... Posted Yesterday in Daily MedNews.
WEDNESDAY, Sept. 8 -- Out-of-shape men who work long hours more than double their risk of dying from heart disease compared to non-fit men working fewer hours, researchers report.
The study also found that when men are fit, working long hours doesn't boost heart risk at all.
The new study included 5,000 Danish men, aged 40 to 59 years, who worked at 14 different companies. Their fitness levels...
Read More... Posted Yesterday in Daily MedNews.
WEDNESDAY, Sept. 8 -- Statins, lauded for their ability to lower cholesterol and prevent heart attacks and strokes, may also reduce the risk of developing rheumatoid arthritis, Israeli researchers report.
"We found that statin users who purchased their medication persistently were less likely to develop rheumatoid arthritis over a long follow-up period," said lead researcher Gabriel Chodick,...
Read More... Posted Yesterday in Clinical Trials.
Novel Therapeutic Approach Directly Regulates A Fundamental
Immune Mechanism, Macrophage Differentiation
MALVERN, Pa.--(BUSINESS WIRE)--Sep 7, 2010 -
Promedior, Inc., a clinical stage biotechnology company
developing novel therapies to treat fibrotic and inflammatory
diseases, announced today the publication of collaborative research
in the
Journal of Allergy and Clinical Immunology...
Read More... Posted Yesterday in Clinical Trials.
ROCKVILLE, Md., Sept. 7 /PRNewswire-FirstCall/ -- Neuralstem,
Inc. (NYSE Amex: CUR) announced that Dr. Shinn-Zong Lin,
Superintendent at China Medical University Hospital, will present
results from a study entitled, "Intracerebral Implantation of
Adherent Human Neural Stem Cells (or Neurals Progenitor Cells or
"NPCs") to Reverse Motor Deficits in Chronic Stroke Rats," at the
Stem...
Read More... Posted Yesterday in Clinical Trials.
-Includes Oral Presentation and 12 posters-
WATERTOWN, Mass.--(BUSINESS WIRE)--Sep 8, 2010 -
Tetraphase Pharmaceuticals, Inc., today announced that 12
poster presentations and an oral summary presentation on
preclinical and clinical data for its lead drug candidate, TP-434,
will be presented at the
2010 Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC) in Boston,...
Read More... Posted Yesterday in New Drug Applications.
NEW YORK--(BUSINESS WIRE)--Sep 7, 2010 - Forest Laboratories,
Inc. announced that the U.S. Food and Drug
Administration's (FDA) Anti-Infective Drugs Advisory Committee
voted 21 – 0 in favor of approval of ceftaroline fosamil for
the treatment of community acquired bacterial pneumonia (CABP) and
voted 18 – 0 in favor of approval for complicated skin and
skin structure infections...
Read More... Posted Yesterday in Clinical Trials.
Novel Cancer Vaccine Demonstrates Significantly Superior Two-
and Three-Year Disease-Free Survival Rates Compared to Historical
Controls
LOS ANGELES--(BUSINESS WIRE)--Sep 8, 2010 - ImmunoCellular
Therapeutics (OTCBB: IMUC), a biotechnology company focused on the
development of novel immune-based cancer therapies, today announced
long-term data from a Phase I clinical trial of ICT-107,...
Read More... Posted Yesterday in Clinical Trials.
Renovo Group plc (LSE : RNVO), the biopharmaceutical company
developing drugs to reduce scarring, improve wound healing and
enhance tissue regeneration, today announces that its Phase I dose
ranging clinical trials designed to establish the safety of
Juvista® following the surgical excision of bilateral earlobe
keloids met all primary safety objectives.
As anticipated in the protocols, the...
Read More... Posted 2 Days Ago in New Drug Applications.
AstraZeneca today announced that MedImmune, its biologics unit,
has received a second complete response letter (CRL) on motavizumab
from the U.S. Food and Drug Administration (FDA).
Based on the preliminary assessment of the CRL, it contains the
following requirements that the company should address to advance
the motavizumab registration:
The FDA has requested evidence from an additional...
Read More... Posted 2 Days Ago in New Drug Applications.
Uppsala, September 7, 2010 - Orexo AB (STO: ORX) announces that
the US Food and Drug Administration ("FDA") has informed Orexo's
partner, ProStrakan Group plc (LSE: PSK), the international
specialty pharmaceutical company, that it will not yet be making a
decision under the Prescription Drug User Fee Act ("PDUFA") for
Abstral.
Discussions between ProStrakan and the FDA on the review...
Read More... Posted 2 Days Ago in Pharma Industry News.
From Canadian Press DataFile (September 6, 2010)
LONDON -- GlaxoSmithKline’s controversial diabetes pill
Avandia should be pulled from the U.K. market because of concerns
that the drug can increase the risk of heart attacks, British drug
regulators said Monday.
The Medicines and Healthcare products Regulatory Agency (MHRA)
said an independent panel of experts had advised it that the...
Read More... Posted 2 Days Ago in Pharma Industry News.
From Guardian Web (September 7, 2010)
What are we to do about the diminishing power of antibiotics - once
the miracle drugs that looked set to end infectious diseases? We
know the problem is becoming very serious - here is a piece I wrote
about the alarming prospects for a future without antibiotics.
But we don’t hear much in the way of imaginative answers.
So it’s refreshing to read...
Read More... Posted 6 Days Ago in Pharma Industry News.
New antimalarial drug candidate with novel mechanism of action
has the potential to rapidly clear a Plasmodium infection upon
administration of a single oral dose, as published in Science
Novartis led collaboration includes The Scripps Research Institute,
the Swiss Tropical and Public Health Institute, with major support
from the Wellcome Trust, Medicines for Malaria Venture, the...
Read More... Posted 6 Days Ago in Pharma Industry News.
-Research: Oral bisphosphonates and risk of cancer of the
esophagus, stomach and colorectum: Case-control analysis within a
UK primary care cohort
LONDON, Sept. 2, 2010-People who take oral bisphosphonates for
bone disease over five years may be doubling their risk of
developing oesophageal cancer (cancer of the gullet), according to
a new study published on bmj.com today.
Oral...
Read More... Posted 6 Days Ago in Pharma Industry News.
Qiuping Gu, M.D., Ph.D.; Charles F. Dillon, M.D., Ph.D.; and
Vicki L. Burt, Sc.M., R.N.
Key findings
Over the last 10 years, the percentage of Americans who took at
least one prescription drug in the past month increased from 44% to
48%. The use of two or more drugs increased from 25% to 31%. The
use of five or more drugs increased from 6% to 11%.
In 2007-2008, 1 out of every 5 children and 9 out...
Read More... Posted 1 Weeks Ago in New Drug Approvals.
IRVINE, Calif.--(BUSINESS WIRE)--Aug 31, 2010 - Allergan, Inc. today announced the United States Food and Drug
Administration (FDA) has approved Lumigan
(bimatoprost ophthalmic solution) 0.01% as a first-line therapy
indicated for the reduction of elevated intraocular pressure (IOP)
in patients with open-angle glaucoma or ocular hypertension.
Lumigan 0.01% is an optimized reformulation...
Read More... Posted 1 Weeks Ago in New Drug Approvals.
Richmond, VA (31st August 2010) – Reckitt Benckiser Pharmaceuticals Inc. today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) to manufacture and market Suboxone sublingual film. Suboxone sublingual film has been developed through an exclusive agreement with MonoSol Rx, utilising its proprietary PharmFilm technology, to...
Read More... Posted 1 Weeks Ago in New Drug Applications.
WATERTOWN, Mass.--(BUSINESS WIRE)--Aug 31, 2010 - pSivida Corp., a leader in the development of sustained
release back of the eye drug delivery systems for
difficult-to-treat conditions, today announced that its licensee,
Alimera Sciences has been notified that the U.S. Food
and Drug Administration (FDA) has granted Priority Review status
for the New Drug Application (NDA) filed for Iluvien...
Read More... Posted 1 Weeks Ago in New Drug Applications.
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Aug 30, 2010 - Eisai Inc.
announced today that it has received notification from the U.S.
Food and Drug Administration (FDA) that the agency expects to
complete priority review of the eribulin mesylate New Drug
Application (NDA) for locally advanced or metastatic breast cancer
on or before December 30, 2010, which is a three month extension
from the...
Read More... Posted 1 Weeks Ago in New Drug Approvals.
EAST HANOVER, N.J., Aug. 27 /PRNewswire/ -- The US Food and Drug
Administration (FDA) approved Tekamlo (aliskiren and
amlodipine) tablets, a single-pill for the treatment of high blood
pressure combining the only approved direct renin inhibitor,
Tekturna (aliskiren), with the widely used calcium channel
blocker amlodipine. Tekamlo is approved as initial therapy for
patients who are likely...
Read More... Posted 3 Weeks Ago in New Drug Approvals.
ROCKVILLE, Md., Aug. 13, 2010--The U.S. Food and Drug
Administration today approved ella (ulipristal acetate)
tablets for emergency contraception. The prescription-only product
prevents pregnancy when taken orally within 120 hours (five days)
after a contraceptive failure or unprotected intercourse. It is not
intended for routine use as a contraceptive.
ella is a progesterone...
Read More... Posted 4 Weeks Ago in New Drug Approvals.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug 10, 2010 -
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration
(FDA) approved increasing the length of therapy with Valcyte
(valganciclovir hydrochloride) in adult kidney transplant patients
at high risk for cytomegalovirus (CMV) disease.
The supplemental approval is based on data that...
Read More...
